



## ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting

October 1, 2020

CLEVELAND, Oct. 1, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: [VRAY](#)) today announced that the Company will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting.

### Event:

**Physician-led Webinar for Investors and Analysts at 2020 ASTRO Annual Meeting**

### Date:

Tuesday, October 27, 2020

### Time:

9:00 a.m. – 10:00 a.m. MTN

### Details:

Registration is required to attend and will close an hour prior to the start. Please register at [https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm\\_bmc\\_source=Press](https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm_bmc_source=Press). An archived replay of the meeting will be available within 24 hours on ViewRay's investor relations website at <http://investors.viewray.com/events-and-presentations/upcoming-events>.

### Guest Speakers:

Dr. Michael Chuong is a board-certified radiation oncologist with Miami Cancer Institute, a part of Baptist Health South Florida. He is the Physician Director of the MRI-Guided Radiation Therapy Program, and the Director of Radiation Oncology Clinical Research. As an internationally recognized expert in the use of radiation therapy for gastrointestinal cancers, he serves on several national committees including the NRG Oncology GI committee. He is also the Principal Investigator of several clinical trials exploring novel combinations of advanced radiation technologies with systemic therapies such as immunotherapy.

Dr. Ray Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at DFBWCC. He led the implementation of MR-guided radiation therapy at Dana Farber and is a member of the Department's MRIdian Adaptive Treatment Team.

A question and answer session will be held at the end of the presentation.

### About ViewRay

ViewRay, Inc. (Nasdaq: [VRAY](#)), designs, manufactures and markets the MRIdian<sup>®</sup> radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's anticipated future operating and financial performance, and ViewRay's conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

SOURCE ViewRay, Inc.

## Related Links

<http://www.viewray.com>